Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy buff.ly/47hR8M8 Charles Hesswani Gautier Marcq Ronald Kool Jose Joao Mansure Fadi Brimo David M. Berman #bladdercancer

Charles Hesswani and Chelsea Jackson showing immunohistochemistry-based #MIBC molecular subtyping was not associated with response nor survival in patients treated with radiation. Great collaboration with David M. Berman and team. eu-openscience.europeanurology.com/article/S2666-…

The National Comprehensive Cancer Network (NCCN) Bladder Cancer Guidelines v1.2024 are now available. It has been a very active time in bladder cancer therapeutic development. Important updates on the treatment of locally advanced/metastatic disease and in many other areas. #BladderCancer nccn.org/home

⚡️ Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis #BladderCancer Ronald Kool sciencedirect.com/science/articl…

FGFR3 mutations are frequent alterations in urothelial cancer, but 🚨: ➡️ NMIBC: ~50% are mutated ➡️ MIBC: ~10% are mutated ➡️ UTUC stage independent: ~ 30% are mutated ➡️ mUC (=bc + UTUC): ~15-20 % are mutated Fusions are very rare throughout all entities! Frequency is ~1%‼️

Great session discussing evolving mCRPC treatments here in Curitiba Brazil with Jônatas Pereira and Ronald Kool! DCI Center for Prostate & Urologic Cancers

Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer out on ASTRO Red Journal Study compares the oncologic outcomes of patients with non-metastatic muscle-invasive #BladderCancer (MIBC) who underwent

Really important and been saying this for many years so good to see other sources supporting. Extent of debulking prognostic but not therapeutic nor practiced in other cancers. Pts in BC2001 with biopsy only did no differently to those with resections

Following IPTW, complete transurethral resection prior to radiation therapy for muscle-invasive bladder cancer was not associated with neither OS,CSS nor MFS. Is complete TUR, in large part, a surrogate for clinical stage?Pier Paolo Avolio redjournal.org/article/S0360-…

A pleasure to finally share our findings of a large RCT of radical cystectomy patients from 10 Canadian institutions. To our shock, TXA did not reduce transfusion. Thank you to the patients, collaborators, and the many research staff. Wes Kassouf Dan McIsaac CIHR

Just in 👉 Journal of Clinical Oncology Benefit of Whole-Pelvis Radiation ☢️ for Patients With #MIBC ascopubs.org/doi/10.1200/JC… 👇👇👇TWEETORIAL 👇👇👇

Congratulations Gautier Marcq Ronald Kool and all on moving this field forward. As patients’ profiles who opt for #chemoradiation #TMT is changing to include healthier patients with higher risk muscle-invasive #bladdercancer, pelvic nodal radiation becomes relevant and important

#HoLEP as a safe option for deobstruction in the setting of advanced prostate adenocarcinoma, T4 lesion is not a restriction for the technique. Patient with invasive and metastatic lesion of the rectum in retention. Laser cyberHo (virtual basket mode): 2J40Hz Quanta Surgery

Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis by Ronald Kool Full article: buff.ly/4gdkIY8 #UroSoMe #MedTwitter

🥨 SunRise 4 shows NeoAdj TAR 200 +/- cetrelimab is safe - ☣️Low G3 toxicity - ⛔️Low treatment discontinuation - 🔪No negative effect on cystectomy. 🦀Anxiously awaiting oncological outcomes! #EAU25

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…